Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial
Gavin Brittain, Jennifer Petrie, Kate E M Duffy, Rachel Glover, Katie Hullock, Diana Papaioannou, Elisa Roldan, Colette Beecher, Matthew Bursnall, Olga Ciccarelli, Alasdair J Coles, Cindy Cooper, Gavin Giovannoni, Ian Gabriel, Majid Kazmi, Charalampia Kyriakou, Richard Nicholas, David Paling, Andy Peniket, Neil Scolding, Eli Silber, Thushan de Silva, Annalena Venneri, Stephen J Walters, Carolyn Young, Paolo A Muraro, Basil Sharrack, John A Snowden
BMJ Open Feb 2024, 14 (2) e083582; DOI: 10.1136/bmjopen-2023-083582